Newsroom | 4218 results

Sorted by: Latest
Neurology
-

VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial

SAN JOSE, Calif.--(BUSINESS WIRE)--VSee Health, Inc. (Nasdaq: VSEE) a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based out of UCLA—the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke surviv...
-

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that it will present data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) in an oral presentation at Cure SMA’s Annual SMA Research & Clinical Care Meeting being held June 25-27, 2025, in Anaheim, California....
-

INBRAIN Neuroelectronics es nombrada pionera tecnológica 2025 por el Foro Económico Mundial

BARCELONA, España--(BUSINESS WIRE)--INBRAIN Neuroelectronics, empresa especializada en neurotecnología en fase clínica que desarrolla interfaces entre el cerebro y el ordenador (brain-computer interfaces, BCI) de precisión con grafeno, ha anunciado hoy que ha sido seleccionada como Pionera tecnológica de 2025 por el Foro Económico Mundial. Este reconocimiento prestigioso destaca la labor pionera de INBRAIN en el desarrollo de terapias neuroelectrónicas inteligentes que aplican el grafeno para t...
-

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (...
-

INBRAIN Neuroelectronics Named 2025 World Economic Forum Technology Pioneer

BARCELONA, Spain--(BUSINESS WIRE)--INBRAIN Neuroelectronics Named 2025 World Economic Forum Technology Pioneer...
-

New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing

BOSTON--(BUSINESS WIRE)--Data from Delve Bio shows the impact of metagenomic sequencing to transform meningitis and encephalitis diagnostics compared to traditional testing....
-

Scientists at City of Hope Discover How Tiny Parts of Cells Stay Organized, Adding New Insights For Blocking Cancer Growth

LOS ANGELES--(BUSINESS WIRE)--A team of international researchers led by scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center named a Top 5 “Best Hospital” in the nation for cancer care by U.S. News & World Report, provide the most thorough account yet of an elusive target for cancer treatment. Published today in Science Advances, the study suggests a complex signaling process inv...
-

Behavioral Health Expert from The Standard to Present on Neurodiversity in the Workplace at SHRM25 Annual Conference on July 1

PORTLAND, Ore.--(BUSINESS WIRE)--Dan Jolivet, Workplace Possibilities practice consultant for The Standard, will present Neurodiversity in the Workplace: Employee Expectations and Employer Obligations on July 1 at the 2025 Society for Human Resource Management annual conference. The SHRM25 event, recognized as the largest HR conference in the world, includes four days of educational sessions, professional development and networking opportunities to help HR professionals elevate their expertise...
-

Chiesi Global Rare Diseases assegna finanziamenti per la ricerca per promuovere l'innovazione nelle malattie lisosomiali

PARMA, Italia--(BUSINESS WIRE)--Chiesi Global Rare Diseases, una business unit del Gruppo Chiesi, creata per offrire soluzioni innovative alle persone affette da malattie rare, oggi ha annunciato i destinatari del suo programma di finanziamenti per la ricerca "Find For Rare". L'iniziativa di borse per la ricerca, guidata da esperti e valutata in modo indipendente, mira a migliorare la cura e la gestione dei pazienti riconoscendo la ricerca innovativa in tre malattie lisosomiali: la malattia di...
-

Chiesi Global Rare Diseases otorga becas de investigación para impulsar la innovación en el ámbito de las enfermedades lisosomales

PARMA, Italia--(BUSINESS WIRE)--Chiesi Global Rare Diseases, una unidad de negocio del Grupo Chiesi que se creó para brindar soluciones innovadoras a las personas que padecen enfermedades raras, anunció el día de hoy los beneficiarios de su programa de becas de investigación "Find For Rare". Esta iniciativa de becas de investigación, que fue evaluada de forma independiente y dirigida por expertos, tiene como objetivo mejorar la atención y el tratamiento de los pacientes mediante el reconocimien...